The global arthropod-borne viral infections testing market is projected to experience significant growth, with its valuation expected to reach USD 1.9 billion by 2029. This growth, representing a robust Compound Annual Growth Rate (CAGR) of 5.6% from 2022, underscores the rising demand for advanced diagnostic solutions to combat the spread of arboviral diseases worldwide.
Arboviral diseases, transmitted to humans through the bites of arthropods such as mosquitoes and ticks, remain a pressing global public health challenge. In 2022, the arthropod-borne viral infections testing market was valued at USD 1.3 billion, making up 4.4% of the global infectious disease diagnostics market, which had a total valuation of USD 28 billion in 2021.
While the market shows strong potential for growth, certain challenges remain. Accessibility to testing methods in low-income economies is hindered by high healthcare costs and a lack of awareness surrounding infectious diseases, slowing the market’s expansion in these regions. Additionally, macroeconomic factors such as disease epidemiology, biologics licensing, and product patenting continue to influence market dynamics. The impacts of climate change, urbanization, and global trade further contribute to the spread of disease vectors and arboviruses, increasing the risk of outbreaks.
“While challenges persist, the evolving landscape presents opportunities for positive growth outlook,” stated Future Market Insights (FMI). “As we continue to navigate dynamic industry variables, advancements in diagnostic technologies and increased awareness about arboviral diseases will be key to addressing this global health concern.”
In response to these challenges, stakeholders within the arthropod-borne viral infections testing market are committed to driving innovation and collaboration. With a focus on improving diagnostic solutions, these efforts are expected to enhance disease management and improve public health outcomes on a global scale.
As the market continues to evolve, the emphasis on technological advancements, coupled with heightened awareness, positions the arthropod-borne viral infections testing market for sustained growth, ultimately contributing to the global fight against infectious diseases.
The factors you’ve mentioned definitely favor the market potential for arthropod-borne viral infections testing:
Resurgence of Threats:
- Past Epidemics: Dengue and Zika virus outbreaks highlight the devastating impact of these infections.
- Unpredictable Nature: The re-emergence of these diseases underlines the need for constant vigilance and improved diagnostic tools.
Growing Government Focus:
- Public Health Initiatives: Increased government efforts to combat arboviral infections create a demand for better testing solutions.
- Global Collaboration: Programs like GEIS showcase a commitment to international cooperation in disease surveillance and mitigation.
These points demonstrate a strong need for accurate and efficient testing methods to identify and control arthropod-borne viral infections. This translates to a significant market opportunity for companies developing and providing such tests.
Growing Need for Market Insights: Access Our Full Report for Thorough Analysis and Trends!
Competitive Landscape:
Providers of testing for arthropod-borne viral infections are channeling investments into advancing the research and development of rapid test kits, aiming for swift and accurate diagnosis with minimal margin of error.
- In November 2021, Achico, a healthcare technology firm based in Switzerland, unveiled its breakthrough in the development of diagnostic kits for dengue fever. These innovative kits rely on Achico’s DNA aptamer technology platform, which has already demonstrated its effectiveness in diagnosing COVID-19.
Key Companies Profiled:
- Thermo Fisher Scientific Inc.
- Roche Molecular Systems Inc.
- bioMérieux SA
- InBios International Inc.
- NovaTec Immundiagnostica GmbH
- Euroimmun AG (Sub. PerkinElmer)
- Quest Diagnostics
- Certest Biotec S.L.
- Response Biomedical Corp.
- Chembio Diagnostic Systems Inc.
- Abbott Laboratories
Key Segments of Arthropod-borne Viral Infections Testing Industry Survey:
Arthropod-borne Viral Infections Testing Market by Test Type:
- ELISA-based Tests for Arthropod-borne Viral Infections Testing
- RT-PCR-based Tests for Arthropod-borne Viral Infections Testing
- Immunochromatography Rapid Diagnosis for Arthropod-borne Viral Infections Testing
Arthropod-borne Viral Infections Testing Market by End User:
- Arthropod-borne Viral Infections in Testing Hospitals
- Arthropod-borne Viral Infections in Public Health Laboratories
- Arthropod-borne Viral Infections in Diagnostic Centres
- Others
Arthropod-borne Viral Infections Testing Market by Region:
- North America Arthropod-borne Viral Infections Testing Market
- Latin America Arthropod-borne Viral Infections Testing Market
- Europe Arthropod-borne Viral Infections Testing Market
- East Asia Arthropod-borne Viral Infections Testing Market
- South Asia & Pacific Arthropod-borne Viral Infections Testing Market
- Middle East & Africa (MEA) Arthropod-borne Viral Infections Testing Market
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
